Cellectar Biosciences, Inc.

Contributing Author

Recent Articles by Cellectar Biosciences, Inc.

Jul-02	Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option CLRB GlobeNewswire
Jul-01	Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering CLRB GlobeNewswire
Jun-26	Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement CLRB GlobeNewswire
Jun-24	Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) CLRB GlobeNewswire
Jun-18	Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split CLRB GlobeNewswire
Jun-11	Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma CLRB GlobeNewswire
Jun-05	Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules CLRB GlobeNewswire
Jun-04	Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) CLRB GlobeNewswire
May-13	Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update CLRB GlobeNewswire
May-07	Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 CLRB GlobeNewswire